SG11202011139YA - Protein binding nkg2d, cd16 and a fibroblast activation protein - Google Patents
Protein binding nkg2d, cd16 and a fibroblast activation proteinInfo
- Publication number
- SG11202011139YA SG11202011139YA SG11202011139YA SG11202011139YA SG11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA SG 11202011139Y A SG11202011139Y A SG 11202011139YA
- Authority
- SG
- Singapore
- Prior art keywords
- protein
- fibroblast activation
- binding nkg2d
- protein binding
- nkg2d
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 230000004913 activation Effects 0.000 title 1
- 210000002950 fibroblast Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862672299P | 2018-05-16 | 2018-05-16 | |
PCT/US2019/032582 WO2019222449A1 (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011139YA true SG11202011139YA (en) | 2020-12-30 |
Family
ID=68540990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011139YA SG11202011139YA (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210363261A1 (ko) |
EP (1) | EP3793605A4 (ko) |
JP (2) | JP2021523913A (ko) |
KR (1) | KR20210010508A (ko) |
CN (1) | CN112423788A (ko) |
AU (1) | AU2019271263A1 (ko) |
BR (1) | BR112020023299A2 (ko) |
CA (1) | CA3100234A1 (ko) |
MX (1) | MX2020012273A (ko) |
SG (1) | SG11202011139YA (ko) |
WO (1) | WO2019222449A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
BR112020016190A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Domínios variáveis de anticorpos direcionando o receptor nkg2d |
WO2022165019A1 (en) * | 2021-01-27 | 2022-08-04 | Georgetown University | Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration |
EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
MA34519B1 (fr) * | 2010-08-13 | 2013-09-02 | Roche Glycart Ag | Anticorps anti-fap et procédés d'utilisation |
CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
AU2016206707A1 (en) * | 2015-01-14 | 2017-08-10 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
CA3011535A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
-
2019
- 2019-05-16 JP JP2020564167A patent/JP2021523913A/ja active Pending
- 2019-05-16 BR BR112020023299-8A patent/BR112020023299A2/pt unknown
- 2019-05-16 SG SG11202011139YA patent/SG11202011139YA/en unknown
- 2019-05-16 EP EP19803947.1A patent/EP3793605A4/en active Pending
- 2019-05-16 KR KR1020207035733A patent/KR20210010508A/ko unknown
- 2019-05-16 US US17/055,792 patent/US20210363261A1/en active Pending
- 2019-05-16 MX MX2020012273A patent/MX2020012273A/es unknown
- 2019-05-16 CN CN201980047481.2A patent/CN112423788A/zh active Pending
- 2019-05-16 CA CA3100234A patent/CA3100234A1/en active Pending
- 2019-05-16 AU AU2019271263A patent/AU2019271263A1/en active Pending
- 2019-05-16 WO PCT/US2019/032582 patent/WO2019222449A1/en unknown
-
2023
- 2023-10-25 JP JP2023183225A patent/JP2023182838A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023182838A (ja) | 2023-12-26 |
BR112020023299A2 (pt) | 2021-02-02 |
WO2019222449A8 (en) | 2020-12-10 |
JP2021523913A (ja) | 2021-09-09 |
CN112423788A (zh) | 2021-02-26 |
CA3100234A1 (en) | 2019-11-21 |
US20210363261A1 (en) | 2021-11-25 |
AU2019271263A1 (en) | 2020-12-03 |
KR20210010508A (ko) | 2021-01-27 |
EP3793605A4 (en) | 2022-03-30 |
WO2019222449A1 (en) | 2019-11-21 |
EP3793605A1 (en) | 2021-03-24 |
MX2020012273A (es) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280673A (en) | Proteins that bind nkg2d, cd16, and tumor-associated antigen | |
SG11202011139YA (en) | Protein binding nkg2d, cd16 and a fibroblast activation protein | |
IL270794A (en) | NKG2D binding protein, CD16 and ROR1 or ROR2 | |
IL281323A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
IL281305A (en) | Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1 | |
IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
EP3582806A4 (en) | HER2, NKG2D AND CD16 BOUND PROTEINS | |
IL292261A (en) | Proteins that bind nkg2d, cd16 and flt3 | |
IL270803A (en) | NKG2D, CD16 and tumor-associated antigen binding protein | |
IL268790A (en) | CD33, NKG2D and CD16 binding proteins | |
IL272706A (en) | Proteins that bind D2NKG, 16CD, and tumor-associated antigen | |
IL270801A (en) | NKG2D, CD16 and tumor-associated antigen binding protein | |
EP3681532A4 (en) | NKG2D, CD1 6 AND TYPE LECTIN LIKE MOLECULE 1 (CLL-1) BINDING PROTEINS | |
IL272374A (en) | NKG2D, CD16, and FLT3 binding proteins | |
IL268574A (en) | proteins that bind psma, nkg2d, and cd16 | |
IL268768A (en) | Proteins binding gd2, nkg2d and cd16 | |
IL280656A (en) | Multispecific binding proteins that bind HER2, NKG2D, and CD16 and methods of use | |
IL268766A (en) | Proteins that bind NKG2D, CD123, and CD16 | |
IL280618A (en) | Proteins that bind NKG2D, CD16 and tumor-associated antigen | |
EP3790585A4 (en) | NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEIN | |
IL311617A (en) | NKG2D, CD16 and BAFF-R binding proteins | |
ZA201905273B (en) | Proteins binding psma, nkg2d and cd16 |